Immutep Ltd Borrow Rate Increases to 117.72%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy IMMP?
Latest data shows the largest indicative borrow rate increases among liquid option names include: Immutep Ltd (IMMP) 117.72% +5.51, Merlin Inc (MRLN) 86.35% +3.04, T-REX 2X Long BMNR Daily Target ETF (BMNU) 18.58% +0.98, PROSHARES ULTRA BITCOIN ETF (BITU) 8.22% +0.65, CrowdGather Inc (CRWG) 8.91% +0.51, iShares Germany (EWG) 8.37% +0.50, LAR Stock (LAR) 1.98% +0.50, Canadian Natural (CNQ) 0.76% +0.46, ProShares UltraShort QQQ (QID) 2.60% +0.45, and Red Cat Holdings (RCAT) 2.05% +0.43.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMMP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMMP
Wall Street analysts forecast IMMP stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.470
Low
12.00
Averages
12.00
High
12.00
Current: 0.470
Low
12.00
Averages
12.00
High
12.00
About IMMP
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immutep Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Immutep for violating §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between March 24, 2025, and March 12, 2026, with a deadline to contact the firm by July 6, 2026, for participation.
- False Statements Exposed: The complaint alleges that Immutep concealed the results of its TACTI-004 trial for eftilagimod alfa, as the company falsely claimed in a Form-K filed with the SEC on January 30, 2026, that the trial was showing “strong operational progress,” despite knowing it would fail to meet primary efficacy endpoints.
- Investor Losses: Following the revelation of the truth about Immutep, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, which undermined investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to reach out to discuss their rights, highlighting the firm's specialization in securities class action lawsuits and shareholder rights litigation aimed at helping investors recover losses.
See More
Immutep Shareholder Class Action Filed
- Class Action Initiation: Bernstein Liebhard LLP announces a securities class action lawsuit on behalf of investors who purchased Immutep Limited ADRs between March 24, 2025, and March 12, 2026, alleging that the company made materially false statements that inflated stock prices, resulting in significant investor losses.
- Legal Procedure Details: Investors wishing to serve as lead plaintiff must file papers by July 6, 2026, with the lead plaintiff representing the class in litigation, although non-lead plaintiffs can still share in any recovery without taking action.
- Lawsuit Background: The lawsuit claims that Immutep made misleading statements regarding its business operations, growth prospects, and financial stability, leading to artificially inflated ADR prices during the class period, causing losses when the truth was revealed.
- Law Firm Credentials: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times in The National Law Journal’s “Plaintiffs’ Hot List,” showcasing its strong reputation in securities litigation.
See More
Immutep Shareholders Alert: Class Action Notice
- Class Action Notice: The Gross Law Firm has issued a notice to shareholders of Immutep Limited (NASDAQ:IMMP), encouraging those who purchased shares during the class period from March 24, 2025, to March 12, 2026, to contact the firm regarding potential lead plaintiff appointment for possible recovery.
- Trial Termination: On March 13, 2026, Immutep announced the discontinuation of its TACTI-004 Phase III clinical trial based on the Independent Data Monitoring Committee's recommendation due to futility, resulting in a dramatic stock price drop from $2.76 to $0.48, representing an approximate 83% decline.
- False Statements Allegations: The complaint alleges that Immutep provided overly positive statements to investors while concealing material adverse facts regarding the efficacy and safety of the TACTI-004 trial, potentially leading to significant investor losses.
- Shareholder Registration Deadline: Shareholders must register for this class action by July 6, 2026, as failing to do so may affect their rights to claim, with the Gross Law Firm committed to providing portfolio monitoring services to keep investors updated on the case's progress.
See More
Shareholder Class Action Filed Against Immutep Limited
- Lawsuit Background: Immutep Limited (NASDAQ: IMMP) is facing a shareholder class action lawsuit alleging false and misleading statements regarding the status and prospects of its TACTI-004 trial, highlighting serious investor concerns about the company's transparency.
- Investor Losses: The lawsuit targets investors who purchased Immutep shares between March 24, 2025, and March 12, 2026, encouraging those who experienced losses during this period to contact legal counsel, reflecting investor unease about the company's future.
- Legal Representation: Holzer & Holzer, LLC, a highly rated law firm in securities litigation, is dedicated to vigorously representing shareholders and investors, underscoring the firm's commitment to protecting investor rights in the face of corporate misconduct.
- Lawsuit Deadline: Investors must apply to be appointed lead plaintiff by July 6, 2026, emphasizing the importance of timely action to ensure their rights are protected in the litigation process.
See More
Immutep Faces Class Action Lawsuit Over Securities Violations
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Immutep, seeking damages for investors who purchased securities between March 24, 2025, and March 12, 2026, reflecting strong investor concerns over potential fraud.
- False Statements Allegations: The complaint alleges that Immutep misrepresented the status and prospects of the TACTI-004 trial, particularly by relying on prior positive results to create an unfounded optimism, severely undermining investor confidence in the company's future.
- Increased Risk Warning: According to the lawsuit, executives at Immutep were aware of the significantly increased risk that the TACTI-004 trial would fail to meet its primary efficacy and safety endpoints, yet they failed to disclose this critical information to investors, potentially leading to substantial losses.
- Investor Rights Protection: Investors have until July 6, 2026, to apply to be lead plaintiffs, with the law firm offering legal support on a contingency fee basis, demonstrating a commitment to protecting investor rights and interests.
See More
Class Action Lawsuit Filed for Immutep ADRs
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, with a deadline of July 6, 2026, for potential lead plaintiffs, highlighting the urgency and opportunity for compensation.
- Lawsuit Background: The lawsuit alleges that Immutep concealed critical internal data regarding the TACTI-004 clinical trial, despite claims of strong progress, resulting in investor losses when the truth was revealed, indicating significant deficiencies in the company's transparency.
- Law Firm's Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, which enhances investor confidence in the firm's capability to handle this case effectively.
- Investor Action Steps: Investors are encouraged to visit the Rosen Law Firm's website or call their toll-free number for more information, demonstrating the firm's proactive approach in supporting investors and ensuring their rights are protected.
See More
Immutep Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Immutep for violating §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between March 24, 2025, and March 12, 2026, with a deadline to contact the firm by July 6, 2026, for participation.
- False Statements Exposed: The complaint alleges that Immutep concealed the results of its TACTI-004 trial for eftilagimod alfa, as the company falsely claimed in a Form-K filed with the SEC on January 30, 2026, that the trial was showing “strong operational progress,” despite knowing it would fail to meet primary efficacy endpoints.
- Investor Losses: Following the revelation of the truth about Immutep, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, which undermined investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to reach out to discuss their rights, highlighting the firm's specialization in securities class action lawsuits and shareholder rights litigation aimed at helping investors recover losses.
See More
Immutep Shareholder Class Action Filed
- Class Action Initiation: Bernstein Liebhard LLP announces a securities class action lawsuit on behalf of investors who purchased Immutep Limited ADRs between March 24, 2025, and March 12, 2026, alleging that the company made materially false statements that inflated stock prices, resulting in significant investor losses.
- Legal Procedure Details: Investors wishing to serve as lead plaintiff must file papers by July 6, 2026, with the lead plaintiff representing the class in litigation, although non-lead plaintiffs can still share in any recovery without taking action.
- Lawsuit Background: The lawsuit claims that Immutep made misleading statements regarding its business operations, growth prospects, and financial stability, leading to artificially inflated ADR prices during the class period, causing losses when the truth was revealed.
- Law Firm Credentials: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times in The National Law Journal’s “Plaintiffs’ Hot List,” showcasing its strong reputation in securities litigation.
See More
Immutep Shareholders Alert: Class Action Notice
- Class Action Notice: The Gross Law Firm has issued a notice to shareholders of Immutep Limited (NASDAQ:IMMP), encouraging those who purchased shares during the class period from March 24, 2025, to March 12, 2026, to contact the firm regarding potential lead plaintiff appointment for possible recovery.
- Trial Termination: On March 13, 2026, Immutep announced the discontinuation of its TACTI-004 Phase III clinical trial based on the Independent Data Monitoring Committee's recommendation due to futility, resulting in a dramatic stock price drop from $2.76 to $0.48, representing an approximate 83% decline.
- False Statements Allegations: The complaint alleges that Immutep provided overly positive statements to investors while concealing material adverse facts regarding the efficacy and safety of the TACTI-004 trial, potentially leading to significant investor losses.
- Shareholder Registration Deadline: Shareholders must register for this class action by July 6, 2026, as failing to do so may affect their rights to claim, with the Gross Law Firm committed to providing portfolio monitoring services to keep investors updated on the case's progress.
See More
Shareholder Class Action Filed Against Immutep Limited
- Lawsuit Background: Immutep Limited (NASDAQ: IMMP) is facing a shareholder class action lawsuit alleging false and misleading statements regarding the status and prospects of its TACTI-004 trial, highlighting serious investor concerns about the company's transparency.
- Investor Losses: The lawsuit targets investors who purchased Immutep shares between March 24, 2025, and March 12, 2026, encouraging those who experienced losses during this period to contact legal counsel, reflecting investor unease about the company's future.
- Legal Representation: Holzer & Holzer, LLC, a highly rated law firm in securities litigation, is dedicated to vigorously representing shareholders and investors, underscoring the firm's commitment to protecting investor rights in the face of corporate misconduct.
- Lawsuit Deadline: Investors must apply to be appointed lead plaintiff by July 6, 2026, emphasizing the importance of timely action to ensure their rights are protected in the litigation process.
See More
Immutep Faces Class Action Lawsuit Over Securities Violations
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Immutep, seeking damages for investors who purchased securities between March 24, 2025, and March 12, 2026, reflecting strong investor concerns over potential fraud.
- False Statements Allegations: The complaint alleges that Immutep misrepresented the status and prospects of the TACTI-004 trial, particularly by relying on prior positive results to create an unfounded optimism, severely undermining investor confidence in the company's future.
- Increased Risk Warning: According to the lawsuit, executives at Immutep were aware of the significantly increased risk that the TACTI-004 trial would fail to meet its primary efficacy and safety endpoints, yet they failed to disclose this critical information to investors, potentially leading to substantial losses.
- Investor Rights Protection: Investors have until July 6, 2026, to apply to be lead plaintiffs, with the law firm offering legal support on a contingency fee basis, demonstrating a commitment to protecting investor rights and interests.
See More
Class Action Lawsuit Filed for Immutep ADRs
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, with a deadline of July 6, 2026, for potential lead plaintiffs, highlighting the urgency and opportunity for compensation.
- Lawsuit Background: The lawsuit alleges that Immutep concealed critical internal data regarding the TACTI-004 clinical trial, despite claims of strong progress, resulting in investor losses when the truth was revealed, indicating significant deficiencies in the company's transparency.
- Law Firm's Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, which enhances investor confidence in the firm's capability to handle this case effectively.
- Investor Action Steps: Investors are encouraged to visit the Rosen Law Firm's website or call their toll-free number for more information, demonstrating the firm's proactive approach in supporting investors and ensuring their rights are protected.
See More
